aurismedical.com
Management Team - Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss
http://www.aurismedical.com/auris-medical/management-team
Bettina M. Stubinski. Anne Sabine Zoller joined us as Senior Legal Counsel in April 2015 and became Auris Medical’s General Counsel in August 2015. Prior to joining Auris Medical, Anne was a Corporate/M&A Counsel with Straumann Group, a dental implant company headquartered in Basel, and an attorney in the Corporate/M&A team of Homburger AG, a Zurich based law firm. She obtained a PhD in law from the University of Zurich and holds an MBA degree. Head of Regulatory and Quality Affairs.
aurismedical.com
Keyzilen™ (AM-101) - Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss
http://www.aurismedical.com/product-candidates/am-101
Keyzilen for the treatment of acute inner ear tinnitus. Keyzilen has the potential to be the first drug to gain approval for treating acute inner ear tinnitus. Keyzilen is currently in Phase 3 clinical development. We have initiated two pivotal clinical trials with highly similar design, one primarly in North America (Efficacy and Safety of Keyzilen in the T. Us 2, or TACTT2) and one in Europe, which we refer to as TACTT3. TACTT2 trial featured in Tinnitus Today of the American Tinnitus Association.
aurismedical.com
The Inner Ear - Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss
http://www.aurismedical.com/inner-ear-disorders/the-inner-ear
The inner ear (auris interna) is the innermost part of the human ear, which also comprises the outer ear (auris externa) and the middle ear (auris media). It comprises the snail shaped cochlea (from Greek: kochlias = snail), which is our organ of hearing, and the vestibular system, which is our our organ of balance. The inner ear is located deep in the skull, and surrounded almost entirely by bone.
aurismedical.com
Milestones - Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss
http://www.aurismedical.com/auris-medical/milestones
License agreement with Xigen. Collaboration agreement with Inserm. Launch of R&D operations in Montpellier, France. EMA grants Orphan Drug Designation for AM-111. FDA grants Orphan Drug Designation for AM-111. Phase I/II clinical trial with AM-111. Start of Phase I/II clinical trial with AM-101. Series B financing round. Move to Basel, Switzerland. Completion of Phase I/II clinical trial with AM-101. Start of first Phase II clinical trial with AM-101 (TACTT0). Start of Phase II clinical trial with AM-111.
aurismedical.com
Menière’s Disease - Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss
http://www.aurismedical.com/inner-ear-disorders/meniere-s-disease
Menière's Disease is a disorder with various fluctuating symptoms: vertigo or strong dizziness, tinnitus, hearing loss and the sensation of pressure or pain in the affected ear. Menière's Disease usually breaks out suddenly, affects most often only one ear, and can arise daily or as infrequently as once a year. Hearing tends to recover between attacks, but over time it becomes worse. Overall, Menière's Disease is a progressive disease.
aurismedical.com
About Us - Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss
http://www.aurismedical.com/auris-medical/about-us
We at Auris Medical are dedicated to developing novel pharmaceutical therapies to protect hearing and to silence tinnitus. Auris Medical is the leading pioneer in the emerging field of cochlear (inner ear) therapies. We have two projects in advanced clinical development:. Keyzilen for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss.
aurismedical.com
Publications - Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss
http://www.aurismedical.com/newsroom/publications
Mühlmeier G, Baguley D, Cox T, Suckfüll M, Meyer T (2016):. Characteristics and spontaneous recovery of tinnitus related to idiopathic sudden sensorineural hearing loss, Otology and Neurotology 37(6), 634 641. Staecker H, Maxwell KS, Morris JR, van de Heyning P, Morawski K, Reintjes F, Meyer T (2015):. Selecting appropriate dose regimens for AM-101 in the intratympanic treatment of acute inner ear tinnitus, Audiology and Neurotology 20(3), 172-182. Molecular mechanisms involved in cochlear implantation t...
aurismedical.com
Board of Directors - Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss
http://www.aurismedical.com/auris-medical/board-of-directors
Chairman of the Board, Chief Executive Officer. James I. Healy. Berndt A. Modig. Mr Papiernik has been a member of our board of directors since April 2013. He is a Managing Partner at Sofinnova Partners, a French venture capital firm, which he joined in 1997. He serves on the boards of directors of Shockwave Medical, Inc., Pixium Vision, Stentys S.A., ReCord Medical, ProQR Therapeutics BV and Mainstay Medical Ltd. He has an MBA from the Wharton School of Business. Calvin W. Roberts.
aurismedical.com
AM-111 - Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss
http://www.aurismedical.com/product-candidates/am-111
AM-111 for the treatment of acute inner ear hearing loss. Auris Medical is developing AM-111 for the treatment of acute inner ear (sensorineural) hearing loss (ASNHL). AM-111 contains the synthetic peptide D-JNKI-1 ( D. Stereoisomer of c- J. AM-111 received orphan drug designation from both EMA and FDA for the treatment of ASNHL. AM-111 has the potential to become the first approved pharmaceutical treatment for ASNHL. Sorineural Hearing Loss T. Reatment; North America and South Korea, initiated in Q2/201...
aurismedical.com
Tinnitus - Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss
http://www.aurismedical.com/inner-ear-disorders/tinnitus
